Developing a cost-effective method for producing therapeutic proteins.
A new platform for inexpensive and scalable recombinant protein and growth factor production to support cell culture applications in therapeutics.
This study is working on a new way to produce important proteins that help with treatments like CAR-T cell therapy, using a special bacteria to make the process faster and cheaper, so more people can benefit from these therapies.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Opera Bioscience, INC. NIH-funded |
| Lab location | 1 site (Evanston, UNITED STATES) |
| Project ID | NIH-11266102 on NIH RePORTER |
What this research studies
This research focuses on creating a new platform that utilizes a bacterial system to produce growth factors and recombinant proteins more efficiently and at a lower cost. By leveraging the type III secretion system of Salmonella enterica, the project aims to streamline the production process, making it easier to generate the proteins needed for various therapeutic applications, including advanced cell therapies like CAR-T cells. This innovative approach could significantly reduce the manufacturing costs associated with these critical biological products, thereby increasing their accessibility for research and treatment.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include patients who may require CAR-T cell therapies or other treatments that rely on recombinant proteins.
Not a fit: Patients who do not require therapies involving recombinant proteins or growth factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more affordable and accessible therapeutic proteins, enhancing treatment options for patients requiring advanced therapies.
How similar studies have performed: Other research has shown promise in using bacterial systems for protein production, indicating that this approach could be effective.
Where this research is happening
Evanston, UNITED STATES
- Opera Bioscience, INC. — Evanston, United States (Active)
Researchers
- Principal investigator: Liang, Julie Ming — Opera Bioscience, INC.
- Study coordinator: Liang, Julie Ming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.